Journey Strategic Wealth LLC Buys 1,181 Shares of Zoetis Inc. $ZTS

Journey Strategic Wealth LLC raised its stake in Zoetis Inc. (NYSE:ZTS) by 53.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,409 shares of the company’s stock after acquiring an additional 1,181 shares during the quarter. Journey Strategic Wealth LLC’s holdings in Zoetis were worth $532,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of Zoetis by 0.8% in the second quarter. Vanguard Group Inc. now owns 41,886,987 shares of the company’s stock valued at $6,532,276,000 after purchasing an additional 330,823 shares in the last quarter. Geode Capital Management LLC boosted its position in Zoetis by 0.9% in the 2nd quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock valued at $1,721,356,000 after buying an additional 95,294 shares during the last quarter. Polen Capital Management LLC boosted its position in Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after buying an additional 1,313,653 shares during the last quarter. Northern Trust Corp raised its position in shares of Zoetis by 1.2% during the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after acquiring an additional 78,508 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Zoetis by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock worth $847,293,000 after acquiring an additional 109,791 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ZTS has been the subject of a number of research reports. Stifel Nicolaus lowered their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. Argus reiterated a “buy” rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. JPMorgan Chase & Co. lowered their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Finally, UBS Group cut their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Moderate Buy” and an average price target of $178.89.

Zoetis Stock Up 5.3%

Zoetis stock opened at $122.06 on Friday. The firm has a market capitalization of $53.79 billion, a price-to-earnings ratio of 21.01, a PEG ratio of 2.31 and a beta of 0.90. The company’s 50 day simple moving average is $137.75 and its 200 day simple moving average is $150.17. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $181.85.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period last year, the business posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is presently 33.67%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.